SABSW · As filed with the SEC
SAB Biotherapeutics income statement, by quarter
The statement as SAB Biotherapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) · USD, except per-share amounts
| USD, except per-share amounts | Q2 2026 3 months ended Jun 30, 2026 | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025 3 months ended Dec 31, 2025 | Q3 2025 3 months ended Sep 30, 2025 |
|---|---|---|---|---|
| Research and development | 16,172,000 | 13,397,977 | — | 8,970,010 |
| General and administrative | 7,205,000 | 6,599,759 | — | 3,708,959 |
| Total operating expenses | 23,377,000 | 19,997,736 | — | 12,678,969 |
| Loss from operations | (23,377,000) | (19,997,736) | — | (12,678,969) |
| Changes in fair value of warrant liabilities | (1,111,000) | (482,474) | — | 61,598,908 |
| Interest expense | (62,000) | (62,745) | — | (43,292) |
| Interest income | 1,709,000 | 1,047,197 | — | 655,233 |
| Other income, net | 350,000 | 626,873 | — | 765,881 |
| Warrant Issuance Cost | — | — | — | (4,852,292) |
| Total other income (expense) | 886,000 | 1,128,851 | — | 58,124,438 |
| Net loss | (22,491,000) | (18,868,885) | — | 45,445,469 |
| Other comprehensive income (loss): | ||||
| Unrealized loss, change in fair value of available-for-sale securities, net of reclassification adjustment and tax | — | (546,791) | — | 87,751 |
| Unrealized loss, change in fair value of available-for-sale securities | (717,000) | — | — | — |
| Reclassification adjustment for gain on sale of available-for-sale securities included in net income | 0 | — | — | — |
| Foreign currency translation gain | 10,000 | 137,517 | — | (723) |
| Total comprehensive loss | (23,198,000) | (19,278,159) | — | 45,532,497 |
| Loss per common share attributable to the Company's shareholders | ||||
| Basic loss per common share | (0.28) | (0.35) | — | 0.50 |
| Diluted loss per common share | (0.28) | (0.35) | — | (0.21) |
| Weighted-average common shares outstanding - basic | 79,753,100 | 53,558,639 | — | 10,660,500 |
| Weighted-average common shares outstanding - diluted | 79,753,100 | 53,558,639 | — | 77,863,263 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.